公开(公告)号：US20210309648A1

公开(公告)日：2021-10-07

申请号：US17127350

申请日：2020-12-18

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANGHAI CO., LTD.

Inventor： Jingshan Shen ,  Yang He ,  Zhen Wang ,  Jianfeng Li ,  Yongjian Liu ,  Jin Suo ,  Guanghui Tian ,  Weiming Chen ,  Feipu Yang ,  Yu Wang ,  Xiangrui Jiang ,  Rongxia Zhang ,  Hualiang Jiang

IPC: C07D409/12

Abstract: The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation.

公开(公告)号：US10174011B2

公开(公告)日：2019-01-08

申请号：US15124264

申请日：2015-03-09

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANDONG CO., LTD.

Inventor： Hualiang Jiang ,  Zhen Wang ,  Jianfeng Li ,  Rongxia Zhang ,  Yang He ,  Yongjian Liu ,  Minghao Bi ,  Zheng Liu ,  Guanghui Tian ,  Weiming Chen ,  Feipu Yang ,  Chunhui Wu ,  Yu Wang ,  Xiangrui Jiang ,  Jingjing Yin ,  Guan Wang ,  Jingshan Shen

IPC: C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00 ,  A61K31/496 ,  A61K31/519 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/55

Abstract: The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

公开(公告)号：US20240226127A1

公开(公告)日：2024-07-11

申请号：US18287722

申请日：2022-04-21

Applicant: VIGONVITA LIFE SCIENCES CO., LTD.

Inventor： Yang LEI ,  Gang CAO ,  Rong HU

IPC: A61K31/7052 ,  A61K31/14 ,  C07H17/02

CPC classification number: A61K31/7052 ,  A61K31/14 ,  C07H17/02

Abstract: The present disclosure relates to a nucleoside compound and an application thereof in the treatment of feline infectious peritonitis. The compound belongs to the GS-441524 analogues. The compound has little toxic effect on normal cat cells, while it has a significant inhibitory effect on feline coronavirus. The compound can be used to prepare feline coronavirus inhibitors for the treatment of feline infectious peritonitis. It has the advantages of good curative effect, high safety, and excellent water solubility, which makes it easier to be absorbed.

公开(公告)号：US20230219993A1

公开(公告)日：2023-07-13

申请号：US17996430

申请日：2021-04-16

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE ,  XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMIY OF SCIENCES ,  VIGONVITA LIFE SCIENCES CO., LTD.

Inventor： Yuanchao XIE ,  Gengfu XIAO ,  Yang HE ,  Leike ZHANG ,  Heji Akber AISA ,  Hualiang JIANG ,  Jingshan SHEN

IPC: C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC classification number: C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia
(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

公开(公告)号：US11384073B2

公开(公告)日：2022-07-12

申请号：US17127350

申请日：2020-12-18

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANGHAI CO., LTD.

Inventor： Jingshan Shen ,  Yang He ,  Zhen Wang ,  Jianfeng Li ,  Yongjian Liu ,  Jin Suo ,  Guanghui Tian ,  Weiming Chen ,  Feipu Yang ,  Yu Wang ,  Xiangrui Jiang ,  Rongxia Zhang ,  Hualiang Jiang

IPC: C07D409/12

Abstract: The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation.

公开(公告)号：US20240140975A1

公开(公告)日：2024-05-02

申请号：US18519408

申请日：2023-11-27

Applicant: Shanghai Institute of Materia Medica, Chinese Academyof Sciences ,  Wuhan Institute ofVirology, Chinese Academy of Science ,  Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Science ,  Vigonvita Life Sciences Co., Ltd.

Inventor： Yuanchao XIE ,  Gengfu Xiao ,  Yang He ,  Leike Zhang ,  Haji Akber Aisa ,  Hualiang Jiang ,  Jingshan Shen

IPC: C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC classification number: C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

公开(公告)号：US11919923B2

公开(公告)日：2024-03-05

申请号：US17996430

申请日：2021-04-16

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE ,  XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMY OF SCIENCES ,  VIGONVITA LIFE SCIENCES CO., LTD.

Inventor： Yuanchao Xie ,  Gengfu Xiao ,  Yang He ,  Leike Zhang ,  Haji Akber Aisa ,  Hualiang Jiang ,  Jingshan Shen

IPC: C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC classification number: C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

公开(公告)号：US10100044B2

公开(公告)日：2018-10-16

申请号：US15030331

申请日：2014-10-20

Applicant: SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANGHAI CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Zheng Liu ,  Chunhui Wu ,  Yongjian Liu ,  Rongxia Zhang ,  Yang He ,  Guanghui Tian ,  Jingshan Shen

IPC: C07D333/70 ,  C07D409/12 ,  C07D333/54

Abstract: The present invention relates to the methods for preparing brexpiprazole, the analogs, key intermediates, and salts thereof, specifically, the present invention relates to a new method for preparing brexpiprazole, the analogs, key intermediates, and salts thereof, and the key intermediates, and salts thereof provided during the preparation. The preparation method has a mild reaction condition, stable intermediate, easy operation, and uses cheap and easy-to-get reagents, thus it saves the synthesis cost, shortens the production cycle, improves the yield and product quality, and is suitable for mass production.

公开(公告)号：US10093679B2

公开(公告)日：2018-10-09

申请号：US15509796

申请日：2015-09-11

Applicant: SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD.

Inventor： Jingshan Shen ,  Zheng Liu ,  Zhen Wang ,  Guanghui Tian ,  Jianfeng Li ,  Xiaojun Yang

IPC: C07D261/20 ,  C07D495/04 ,  A61K31/33 ,  A61K31/381 ,  C07D209/14 ,  C07D307/77 ,  C07D231/56 ,  C07D275/04 ,  C07D333/20 ,  A61K31/415 ,  A61K31/42 ,  A61K31/425 ,  C07D333/46

Abstract: Disclosed are aminosulfonyl-based compounds represented by the general formula I or tautomers, enantiomers, racemates or pharmaceutically acceptable salts thereof, a method for preparing the same, pharmaceutical compositions and uses thereof. The compounds can be used to treat epilepsy, convulsions, obesity and the like.

公开(公告)号：US20170298080A1

公开(公告)日：2017-10-19

申请号：US15509796

申请日：2015-09-11

Applicant: SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD.

Inventor： Jingshan SHEN ,  Zheng LIU ,  Zhen WANG ,  Guanghui TIAN ,  Jianfeng LI ,  Xiaojun YANG

IPC: C07D495/04 ,  C07D275/04 ,  C07D261/20 ,  C07D333/20 ,  C07D231/56

CPC classification number: C07D495/04 ,  A61K31/33 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61K31/425 ,  C07D209/14 ,  C07D231/56 ,  C07D261/20 ,  C07D275/04 ,  C07D307/77 ,  C07D333/20 ,  C07D333/46

Abstract: Disclosed are aminosulfonyl-based compounds represented by the general formula I or tautomers, enantiomers, racemates or pharmaceutically acceptable salts thereof, a method for preparing the same, pharmaceutical compositions and uses thereof. The compounds can be used to treat epilepsy, convulsions, obesity and the like.